Naphthyloxazolidone derivatives

Abstract: A naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a lower alkenyloxy group, a lower alkynyloxy group, a mono or di(lower alkyl)aminocarbonyloxy group, a lower alkanoyloxy group or a lower alkoxy group which may have a substituent selected from an aryl group, a cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a lower alkoxy group, cyano group, a di(lower alkyl)amino group, aminocarbonyl group, a lower alkoxycarbonyl group, a lower alkanoyloxy group, a lower alkylthio group, a lower alkylsulfinyl group and a lower alkylsulfonyl group; R² is hydroxy group, a lower alkoxy group, a lower alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a lower alkyl group and a lower alkanoyl group, and a pharmaceutically acceptable salt thereof are disclosed. Said derivative and a pharmaceutically acceptable salt thereof lare useful as an antidepressant.

Description: This invention relates to novel naphthyloxazolidone derivatives which are useful as an antidepressant and processes for preparing the same. Monoamine oxidase (MAO), which catalyzes oxidative deamination of monoamines to produce aldehydes, is classified into two groups (id., MAO-A and MAO-B) according to its substrate specificity: MAO-A catalyses oxidative deamination of neurotransmitters such as serotonin, noradrenarine and the like, whereas MAO-B catalyzes oxidative deamination of phenethylamine, and the like. Known MAO inhibitors which shave been used as the antidepressant have no selective inhibitory activity against MAO-A or MAO-B and show irreversible and long-lasting inhibitory activity. Therefore, the known MAO inhibitors are disadvantageous in that they have side effects such as hepatic injuries, migraine and hypertensive crises after the ingestion of tyramine-containing food [i.e., cheese effect]. An object of the present invention is to provide novel naphthyloxazolidone derivatives which have potent reversible and selective inhibitory activity against MAO-A and are useful as an antidepressant. Other object of the present invention is to provide processes for preparing said naphthyloxazolidone derivatives. Another object of the present invention is to provide novel intermediates of said naphthyloxazolidone derivatives., The present invention relates to a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a lower alkenyloxy group, a lower alkynyloxy group, a mono or di(lower alkyl)aminocarbonyloxy group, a lower alkanoyloxy group or a lower alkoxy group which may have a substituent selected from an aryl group, a cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a lower alkoxy group, cyano group, a di(lower alkyl)amino group, aminocarbonyl group, a lower alkoxycarbonyl group, a lower alkanoyloxy group, a lower alkylthio group, a lower alkylsulfinyl group and a lower alkylsulfonyl group; R² is hydroxy group, a lower alkoxy group, a lower alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a lower alkyl group and a lower alkanoyl group, or a pharmaceutically acceptable salt thereof. Examples of the naphthyloxazolidone derivative (I) of the present inventon include those of the formula (I) in which an aryl group is phenyl group, a cycloalkyl group is a cycloalkyl group of 3 to 6 carbon atoms, and an oxygen-containing heteromonocyclic group is a tetrahydrofuryl group. Among them, preferred compounds include those of the formula (I) in which R¹ is a lower alkenyloxy group, a lower alkanoyloxy group or a lower alkoxy group which may have a substituent selected from cyclopropyl group, hydroxy group and cyano group; R² is a lower alkoxy group. More preferred compounds are those of the formula (I) in which R¹ is a lower alkoxy group which may have a substituent selected from cyclopropyl group and cyano group. Another preferred compounds are those of the formula (I) in which R¹ is at the 6-position of naphthalene ring and the 5-substituted-2-oxazolidon-3-yl group is at the 2-position of naphthalene ring. According to the present invention, the naphthyloxazolidone derivatives (I) can be prepared either by [A] reacting a lower alkyl naphthylcarbamate compound of the formula: wherein R³ is a lower alkyl group and R¹ is the same as defined above, or a salt thereof with an oxirane compound of the formula: wherein R² is the same as defined above, or a salt thereof, or by [B] reacting a naphthalene compound of the formula: wherein X¹ is a reactive residue, R¹ is the same as defined above, or a salt thereof with a 2-oxazolidone compound of the formula: wherein R² is the same as defined above, or a salt thereof. The naphthyloxazolidone derivative of the formula: wherein R¹ is the same as defined above, can also be prepared by [C] condensing a propanediol compound of the formula: wherein R¹ is the same as defined above, or a salt thereof with a carbonyl compound of the formula: CO(X²)₂ (VII) wherein X² is a reactive residue. The naphthyloxazolidone derivative of the formula: wherein R⁴ is a lower alkyl group or a lower alkylsulfonyl group, and R¹ is the same as defined above, can also be prepared by [D] condensing the compound (I-a) with the compound of the formula: R⁴-X³ (VIII) wherein X³ is a reactive residue and R⁴ is the same as defined above. The naphthyloxazolidone derivative of the formula: wherein R² is the same as defined above, can also be prepared by [E] reducing the compound of the formula: wherein R⁵ is an aryl-lower alkyl group, R² is the same as defined above, or a salt thereof. Further, the naphthyloxazolidone derivative of the formula: wherein R⁶ is a lower alkenyl group, a lower alkynyl group, a mono or di(lower alkyl)aminocarbonyl group, a lower alkanoyl group or a lower alkyl group which may have a substituent selected from an aryl group, a cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a lower alkoxy group, cyano group, a di(lower alkyl)amino group, aminocarbonyl group, a lower alkoxycarbonyl group, a lower alkanoyloxy group, a lower alkylthio group, a lower alkylsulfinyl group and a lower alkylsulfonyl group, R² is the same as defined above, can also be prepared by [F] condensing the compound (I-c) or a salt thereof with a compound of the formula: R⁶-X⁴ (IX) wherein X⁴ is a reactive residue, R⁶ is the same as defined above, or a salt thereof. Among the naphthyloxazolidone derivative (I-e), a compound of the formula: wherein R⁷ is cyano group or a lower alkoxycarbonyl group, and R² is the same as defined above, can also be prepared by [G] reacting a compound (I-c) or a salt thereof with a compound of the formula: R⁷-CH=CH₂ (X) wherein R⁷ is the same as defined above. Further, among the naphthyloxazolidone derivative (I-e), a compound of the formula; wherein R⁸ is a lower alkyl group, and R² is the same as defined above, can also be prepared by [H] reacting the compound (I-c) or a salt thereof with a lower alkyl isocyanate. The reaction of the compound (II) with the compound (III) (i.e., Step [A]) can be carried out in the presence of a base. Any conventional base may be used for this reaction. Preferred examples of the base include a tri(lower alkyl)amine, a 4-di(lower alkyl)aminopyridine, an alkali matal hydroxide, an alkali metal alkoxide and the like. The reaction may be carried out in the presence or absence of a solvent such as dimethylformanide, dimethylacetamide, dimethylsulfoxide, xylene or the like. It is preferred to carry out the reaction under heating, for example, at a temperature between 50 and 150 °C, preferably at a temperature between 90 and 110 °C. The reaction of the compound (IV) with the compound (V) (i.e., Step [B]) can be carried out in the presence of an acid acceptor. Examples of the acid acceptor include conventional organic or inorganic bases such as an alkali metal bicarbonate, an alkali metal carbonate, an alkali metal hydride, a tri(lower alkyl)amine and so forth. Examples of the reactive residue (X¹) of the compound (IV) include a conventional reactive residue such as a halogen atom and the like. The reaction may be carried out in the presence or absence of a solvent such as dimethylformanide, dimethylacetamide, dimethylsulfoxide, xylene or the like. It is preferred to carry out the reaction under heating, for example, at a temperature between 150 and 220 °C. In particular, said reaction prefelably proceeds by adding copper power to the reaction system. The condensation reaction of the compound (VI) with the compound (VII) (i.e., Step [C]) can be carried out in the presence of a base. The same bases as mentional in Step [A] are preferably used for the reaction. Examples of the reactive residue (X²) of the compound (VII) include an lower alkoxy group, imidazolyl group, halogen atom and the like. It is preferred to carry out the reaction in a solvent such as toluene, xylene, methylen chloride, chloroform, tetrahydrofuran and so forth and at room temperature or under heating, for example, at a temperature between 10 and 150 °C. The condensation reaction of the compound (I-a) with the compound (VIII) (i.e., Step [D]) can be carried out in the presence or absence of an acid acceptor. The same bases as mentioned in Step [B] are preferably used for the reaction as the acid acceptor. Examples of the reactive residue (X³) of the compound (VIII) include a halogen atom, a lower alkanoyloxy group, a (lower alkyl) sulfonyloxy group, arylsulfonyloxy group and the like. It is preferred to carry out the reaction in a solvent such as acetone, ethyl acetate, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, diethyl ether, dioxane or the like. Said reaction preferably proceeds at room temperature or under heating, for example, at a temperature between 30 and 120 °C. The reduction of the compound (I-d) (i.e., Step [E]) can be conducted in a conventional manner. For example, said reduction is carried out by subjecting the compound (I-d) to catalytic hydrogenation in the presence of palladium-carbon, Raney nickel, Raney cobalt, platinum, rhodium, or the like. The catalytic hydrogenation preferably proceeds in a solvent such as tetrahydrofuran, dioxane, a lower alkanol or the like, under atmospheric pressure or increased pressure and at room temperature or under warming, for example, at a temperature between 10 and 50 °C. The condensation reaction of compound (I-c) with the compound (IX) (i.e., Step [F]) can be carried out in the presence or absence of an acid acceptor. The same organic or inorganic bases as mentioned in Step [B] are prefelably used for the reaction as the acid acceptor. Examples of the reactive residue (X⁴) includes the same as the reactive residue (X³). It is preferred to carry out the reaction in a solvent such as acetone, ethyl acetate, dimethylformamide, dimethylsulfoxide or the like and at room temperature or heating, for example, at a temperature between 30 and 120 °C. The reaction of the compound (I-c) with the compound (X) (i.e., Step [G]) and the reaction of the compound (I-c) with the lower alkyl isocyanate (i.e., Step [H]) can be carried out in the presence of a base. The same bases as mentioned in Step [A] are prefelably used for the reaction, and in addition, benzyltri(lower alkyl)ammonium hydroxide, tetra(lower alkyl)ammonium hydroxide and the like can also be used. The reaction preferably proceeds in a solvent such as tetrahydrofuran, methylene chloride, dimethylformamide, dimethylsulfoxide or the like and at room temperature or under heating, for example, at a temperature between 20 and 80 °C. In the above-mentioned reactions, the starting compounds of the present invention may be used either in a free form or in the form of a salt. For example, the compounds (VI), (I-a) and (I-c), and the compounds (II) to (V), (IX) and (I-d) which have hydroxy group are, if required, used in the form of an alkali metal salt, an alkali earth metal salt, an ammonium salt and the like. On the other hand, the compounds (V) and (VI), and the compounds (II) to (IV), (IX), (I-a), (I-c) and (I-d) which have amino group or mono or di(lower alkyl)amino group are, if required, used in the form of an organic or inorganic acid addition salt. Concomitantly, some of the naphthyloxazolidone derivative (I) of the present invention can, if required, be converted into another naphthyloxazolidone derivative (I) in a conventional manner. For example, when R¹ is nitro group and/or R² is triazo group, said group(s) may be converted into amino group(s) by catalytic hydrogenation. If required, the resulting amino group(s) may be converted into a lower alkanoylamino group(s), or may be converted into hydroxy group(s) or a lower alkoxy group(s) after diazotization of said amino group(s). When R¹ is sulfo group, said group may be converted into aminosulfo group by a conventional amination. Further, when R¹ is a (lower alkyl)thio-substituted-lower alkoxy group, said group may be converted into a (lower alkyl)sulfinyl-substituted-lower alkoxy group or a (lower alkyl)sulfonyl-substituted-lower alkoxy group by oxidation thereof. On the other hand, when R² is a lower alkoxy group, said group may be converted into hydroxy group by hydrolysis thereof, and if required, be converted into a lower alkylsulfonyloxy group in a conventional manner, and if necessary, further converted into a lower alkylamino group or a triazo group. The naphthyloxazolidone derivatives (I) of the present invention include within its scope either one of optically active isomers and the mixtures thereof. Since the reactions of the present invention as mentioned above proceed without accompanying racemization, the compound (I) can be obtained as an optically active compound by using an optically active starting materials. Further, when the naphthyloxazolidone derivative (I) is in the form of a racemic modification, it can be separated into each of two optically active isomers thereof in a conventional manner, for example, by the steps of: (1) treating said compound (I) with an alkali metal hydroxide (e.g., potassium hydroxide), (2) protecting the amino group of the resultant compound with a lower alkoxycarbonyl group, (3) reacting the resultant compound with an optically active 1-(2-naphthylsulfonyl)pyrrolidin-2-carbonyl chloride, (4) separating each of two kinds of resulting diastereomers by taking advantage of difference in solubilities thereof or column chromatography, (5) hydrolyzing each of the diastereomers with an alkali metal hydroxide (e.g., sodium hydroxide), and then, (6) reacting the resultant compound with compound (VII) in the same manner as described in Step [C]. The naphthyloxazolidone derivatives (I) can be used for pharmaceutical use either in a free form or in the form of a pharmaceutically acceptable salt. Examples of the pharmaceutically acceptable salts include salts with an organic or inorganic base such as alkali metal salts (e.g., sodium salt, potassium salt), alkaline earth metal salts (e.g., calcium salt, magnesium salt), ammonium salt and the like, and organic or inorganic acid addtion salts such as hydrochloride, sulfate, acetate, benzensulfonate and the like. The naphthyloxazolidone derivative (I) or a pharmaceutically acceptable salt thereof has excellent reversible and selective MAO-A inhibitory activity. Accordingly, the compound (I) or a pharmaceutically acceptable salt thereof is useful as a therapeutic or prophylactic agent for depressive conditions such as depression, senile depression, abulia, axiety, insomnia, anorexia and the like in warm-blood animals including human beings. In particular, the compound (I) or a pharmaceutically acceptable salt thereof is characterized in that it shows short duration of inhibitory activity and has no side effect such as hepatic injuries, migraine, cheese effect or the like. Moreover, the compound (I) or a pharmaceutically acceptable salt thereof is low in toxicity and have high safety as a pharmaceuticals. For example, when 3-(6-cyanoethoxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone was administered orally to mice at a dose of 2g/kg, no mice died during 2 week-observation period. The naphthyloxazolidone derivative (I) or a pharmaceutically acceptable salt thereof may be administered either orally or parenterally. They may also be used in the form of pharmaceutical preparations such as tablets, capsules, powders, granules, injections and the like, if necessary, in admixture with a pharmaceutically acceptable carrier, diluent or disintegrant. The dose of the naphthyloxazolidone derivative (I) or a pharmaceutically acceptable salt thereof may vary depending on the age, body weight and condition of patients, the kind and severity of diseases to be treated, administration route, etc, but it may usually be in the range of about 0.01 to about 250 mg per kg, preferably about 0.1 to about 30 mg per kg, per day. Among the starting compounds of the present invention, the compounds (II), (V) and (VI) are novel. The compound (II) may be prepared, for example, by reacting a naphthylamine compound of the formula: wherein R¹ is the same as defined above, with a compound of the formula: X⁵-COOR³ (XII) wherein X⁵ is halogen atom and R³ is the same as defined above in the presence of an acid acceptor (e.g., sodium bicarbonate) and in a solvent (e.g., methylene chloride). The compound (V) may be prepared, for example, by reacting an aminopropanol compound of the formula: wherein R² is the same as defined above, with a benzyloxycarbonyl halide or a lower alkoxy-carbonyl halide in the presence of an acid acceptor (e.g., triethylamine) and in a solvent (e.g., tetrahydrofuran), and then, subjectng the resultant compound to intermolecular cyclization in the presence of a base (e.g., sodium hydride). Furthermore, the compound (VI) may be prepared, for example, by reacting the naphthylamine compound (XI) with 2,2-dimethyl-4-tosyloxy-1,3-dioxolane, and then, hydrolyzing the resultant compound in the presence of an acid (e.g., hydrochloric acid). In this specification and Claims, the terms "a lower alkyl group", "a lower alkoxy group", "a lower alkanoyl group", "a lower alkenyl group" and "a lower alkynyl group" represent an alkyl group of one to 6 carbon atoms, an alkoxy group of one to 6 carbon atoms, an alkanoyl group of 2 to 6 carbon atoms, an alkenyl group of 2 to 6 carbon atoms and an alkynyl group of 2 to 6 carbon atoms, respectively. Experiment 1 Inhibitory effect against MAO-A activity of cerebral mitochondorian fraction from rat (in vitro) (Method) A suspension (7 mg protein/ml) of mitochondorial fraction obtained from cerebral tissue of rats in a conventional manner was used as a sample of enzyme, and serotonin was used as the substrate. of MAO-A. The MAO-A activity was estimated in terms of the amount of ammonia produced from serotonin by the enzymatic reaction. Inhibitory rate of the test compounds (10⁻⁷ M) against the MAO-A activity was calculated according to the following equation. NH₃(T): the amount of NH₃ in test tube (addtion of test compound) NH₃(C): the amount of NH₃ in control tube (no addition of test compound) (Results) The results are shown in the following Table 1 Experiment 2 Inhibitory effect against cerebral MAO-A and MAO-B activity in mouse. (Method) A test compound (30 mg/kg) suspended in 0.5% aqueous sodium carboxymethylcellulose (CMC-Na) solution was administered orally to a group of 3 mice. The brain was excised 45 minutes after the administration. A control group was administered with the 0.5% aqueous CMC-Na solution alone. The brain tissue was homogenized in 9 volumes of ice-cold distilled water and the homogenate was used as enzyme. MAO-A activity was estimated in the same manner as described in Experiment 1, whereas MAO-B activity was estimated in terms of the amount of benzaldehyde formed from benzylamine according to the method as described in "The Journal of Laboratory and Clinical Medicine, Vol. 62, P.P.766 - 776 (1963)". Inhibitory rate of the test compound against the MAO-B activity are calculated according to the following equation. BA(T): the amount of benzaldehyde in the medicated group BA(C): the amount of benzaldehyde in the non-medicated control group (Results) The results are shown in the following Table 2. Example 1 (1) A mixture of 16.7g of ethoxycarbonyl chloride and 20ml of methylene chloride is added dropwise to a mixture of 20.0g of 2-naphthylamine, 17.6g of sodium bicarbonate, 100 ml of water and 200ml of methylene chloride under ice-cooling and stirring. The mixture is stirred overnight at room temperature. Chloroform is added to the mixture and the organic layer is separated, dried and treated with charcol. The residue is recrystallized from ethyl acetate - hexane to give 25.26g of N-ethoxycarbonyl-2-naphthylamine. m.p. 69.0 - 70.5 °C (2) A mixture of 3.82g of the product obtained in the the paragraph (1), 3.13g of 2-(methoxymethyl)oxirane and 0.4g of triethylamine is refluxed for 3.5 hours. The reaction mixture is extracted with ethyl acetate. The extract is washed with water, dried and filtered. The filtrate is condensed and the residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (2:3)] to give 3.75g of crude 5-methoxymethyl-3-(2-naphthyl)-2-oxazolidone. The recrystallization of this crude product from ethyl acetate - hexane gives 3.17g of colorless needles. m.p.79.5 - 81.5 °C Example 2 to 5 (1) The corresponding starting compounds are treated in the same manner as described in Example 1-(1) to give compounds shown in Table 3. (2) The products obtained in the paragraph (1) are treated in the same manner as described in Example 1-(2) to give compounds shown in Table 4 Example 6 A mixture of 4.63g of N-ethoxycarbonyl-2-naphthylamine, 4.2g of 2-(butoxymethyl)oxirane and 0.22g of triethylamine is stirred at 100 to 105 °C for 1.5 hours. The reaction mixture is cooled, and the crystalline precipitates are collected by filtration, treated with charcol and recrystallized from ethyl acetate - isopropyl ether - hexane. 4.7g of 3-(2-naphthyl)-5-tert.butoxymethyl-2-oxazolidone are obtained. m.p. 112.5 - 113.0 °C Example 7 (1) 19.69g of triethylamine are added to a solution of 10.23g of 1-amino-3-methoxy-2-propanol in 100ml of tetrahydrofuran. After the mixture is cooled, a solution of 16.60g of benzyloxycarbonyl chloride in 50ml of tetrahydrofuran is added dropwise thereto for 30 minutes. The mixture is stirred at room temperature for one hour. The reaction mixture is diluted with ethyl acetate, washed with water and dried. The residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (2:1)]. 13.2g of 1-benzyloxycarbonylamino-3-methoxy-2-propanol are obtained as colorless oil. (2) 10.2g of the product obtained in the paragraph (1) are dissolved in 200 ml of tetrahydrofuran, and 1.624g of sodium hydride (60% dispersion in oil) are added thereto. The mixture is stirred at room temperature for one hour. Water is added to the reaction mixture and the mixture is extracted with chloroform. The extract is condensed and the residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (3:1)]. 3.36g of 5-methoxymethyl-2-oxazolidone are obtained as colorless oil. (3) 1.2g of sodium methoxide are added to a mixture of 38.44g of 1-amino-3-methoxy-2-propanol and 64.78g of diethyl carbonate. The mixture is stirred at 100 °C for 2.5 days. An excess diethyl carbonate is removed from the mixture. The residue is dissolved in 50 ml of anhydrous tetrahydrofuran, and 1.4g of 63% of sodium hydride are added thereto. The mixture is stirred overnight at room temperature. 4 ml of acetic acid are added to the reaction mixture, and the mixture is stirred at room temperature for 3 hours. Insoluble materials are filtered off. The filtrate is condenced and the residue is distilled under reduced pressure. 42.38g of 5-methoxymethyl-2-oxazolidone are obtained as colorless oil. The physico-chemical properties of this product are identical to those of the compound obtained in the paragraph (2). (4) 6.10g of activated copper powder and 2.76g of sodium carbonate are added to a mixture of 5.24g of the product obtained in the paragraph (2) or (3) and 4.14g of 2-bromonaphthalene. The mixture is stirred at 200°C for 3 hours. After the mixture is cooled, ethyl acetate is added thereto and insoluble materials are filtered off. The filtrate is evaporated under reduced pressure to remove the solvent. The residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (2:3)]. 2.36 g of 5-methoxymethyl-3-(2-naphthyl)-2-oxazolidone are obtained as colorless needles. The physico-chemical properties of this product are identical to those of the compound obtained in Example 1. Examples 8 and 9 The corresponding starting compounds are treated in the same manner as described in Example 7-(4) to give the compounds shown in Table 5. Example 10 (1) 100g of 1,2-epoxypropyl tert.-butyl ether are added dropwise to 500 ml of conc. aqueous ammonia under ice-cooling and the mixture is stirred at room temperature for 20 hours. The reaction mixture is evaporated under reduced pressure to remove the aqueous ammonia. Chloroform is added to the residue. The mixture is dried with potassium carbonate. Insoluble materials are filtered off and the filtrate is evaporated to remove the solvent. The residue is distilled under reduced pressure. 49.3g of 1-amino-3-tert.-butoxy-2-propanol are obtained. b.p. 109 - 110 °C/8 mmHg m.p.41-43 °C (2) A mixture of 49.3g of the product obtained in the paragraph (1), 4.91g of diethyl carbonate and 0.18g of sodium methoxide is heated at 50 °C for 3 hours. About 40ml of ethanol which is produced during the reaction are evaporated. After the reaction is completed, the mixture is evaporated under reduced pressure to remove excess diethyl carbonate . The residue is cooled, and the crystalline precipitates are washed with hexane. 55.4g of 5-tert.-butoxymethyl-2-oxazolidone are obtained as colorless crystals. m.p.57-65 °C (3) 1.1g of the product obtained in the paragraph (2) and 1.0g of 2-benzyloxy-6-bromonaphthalene are treated in the same manner as described in Example 7-(4). 0.73g of 3-(6-benzyloxy-2-naphthyl)-5-tert.-butoxymethyl-2-oxazolidone is obtained as colorless crystals. m.p. 151.5 - 152 °C (ethyl acetate - isopropyl ether) Example 11 (1) 21.0g of tosyl chloride are added portionwise to a mixture of 14.4g of (R)-α,β-isopropylidene glycerol and 60 ml of pyridine under ice-cooling. The mixture is stirred for 4 hours. 50 ml of water are added to the mixture under ice-cooling. The mixture is stirred at room temperature for 10 minutes. The reaction mixture is extracted with diethyl ether, the extract is washed with water and dried. The solvent is removed by evaporation under reduced pressure. 29.5g of (4S)-2,2-dimethyl-4-tosyloxymethyl-1,3-dioxolane are obtained as pale brown oil. Mass (m/z): 276 (M⁺-15), 155, 101, 91 (base), 43 (2) A mixture of 9.51g of the product obtained in the paragraph (1), 5.25g of 6-(cyclopropylmethoxy) naphthylamine, 5.54g of sodium iodide, 6.2g of sodium bicarbonate and 42ml of hexamethylphosphoric triamide is stirred at 120 °C for 11 hours. The reaction mixture is poured into water and extracted with ethyl acetate. The extract is washed with water, dried and evaporated. The residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (1:5)] and recrystallized from ethyl acetate - hexane. 5.88g of (4R)-4-[6-(cyclopropylmethoxy)-2-naphthylaminomethyl]-2,2-dimethyl-1,3-dioxolane are obtained as pale yellow scales. m.p. 108.5 - 109.0 °C [α] 20 / D -12.9° (c=1.089, chloroform) (3) A mixture of 8.09g of the product obtained in the paragraph (2), 35ml of 1N-hydrochloric acid and 80ml of tetrahydrofuran is stirred at 60 °C for 2 hours. The reaction mixture is condensed under reduced pressure. The residue is basified with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The extract is washed with water, dried and evaporated under reduced pressure to remove the solvent. The residue is recrystallized from ethyl acetate - hexane. 6.93g of (2R)-3-(6-cyclopropylmethoxy-2-naphthylamino)-1,2-propandiol are obtained as pale brown scales. m.p. 138.0 - 138.5 °C [α] 20 / D +8.0° (c=0.898, tetrahydrofuran) (4) A mixture of 1.36g of the product obtained in the paragraph (3), 670mg of diethyl carbonate, one ml of toluene and 50mg of sodium methoxide is stirred at 150 °C for one hour. The reaction mixture is evaporated under reduced pressure to remove the solvent. One drop of acetic acid is added to the residue. The residue is purified by silica gel column chromatography [solvent; chloroform - ethyl acetate (1:1 to 1:3)] and recrystallized from ethyl acetate - hexane. 1.06g of (5R)-3-(6-cyclopropylmethoxy-2-naphthyl)-5-hydoroxymethyl-2-oxazolidone are obtained as colorless needles m.p. 181.5 - 182.5 °C [α] 20 / D -61.4° (c=1.031, chloroform) Example 12 A mixture of 626mg of (5R)-3-(6-cyclopropylmethoxy-2-naphthyl)-5-hydroxymethyl-2-oxazolidone, 114mg of sodium hydride (63% dispersion in oil) and 5ml of dimethylformamide is stirred at room teperature for 10 minutes. 350mg of methyl iodide are added to the mixture, and the mixture is stirred at room temperature for 2 hours. 0.1ml of acetic acid is ridded to the reaction mixture. The mixture is poured into water and extracted with ethyl acetate, and the extract is washed with water, dried and evaporated under reduced pressure to remove the solvent. The residue is purified by silica gel column chromatography [solvent: chloroform - ethyl acetate (2:1)] and recrystallized from ethyl acetate - hexane. 501 mg of (5R)-3-(6-cyclopropylmethoxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless scales. m.p. 119.0 - 119.5 °C [α] 20 / D -54.2° (c=1.136, chloroform) Example 13 6.99g of 5-methoxymethyl-3-(7-nitro-2-naphthyl)-2-oxazolidone are suspended in 140ml of acetic acid, and 2.1g of 10% palladium - carbon are added thereto. The mixture is subjected to catalytic hydrogenation under atomospheric pressure at room temperature. The reaction mixture is filtered with celite and the filtrate is evaporated under reduced pressure. The residue is extracted with ethyl acetate and the extract is washed, dried and condensed. The residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (2:1 to 3:1)], and residue is recrystallized from ethyl acetate - isopropyl ether to give 4.96g of 3-(7-amino-2-naphthyl)-5-methoxymethyl-2-oxazolidone. m.p. 98 - 99°C Examples 14 and 15 A solution of 0.97g of sodium nitrite is 6ml of water is added dropwise at 0 to 5 °C to a mixture of 3.47g of 3-(7-amino-2-naphthyl)-5-methoxymethyl-2-oxazolidone, 6ml of water and 3.3ml of conc. hydrochloric acid. After the mixture is stirred for a few minutes, 100 ml of methanol are added thereto. The mixture is stirred at room temperature for 7 hours and then allowed to stand in a refrigerator overnight. The reaction mixture is extracted with ethyl acetate and the extract is washed and dried. The aqueous layer is further extracted with chloroform and the extract is dried. The residue (1.88g) is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (1:1)]. 5-methoxymethyl-3-(7-methoxy-2-naphthyl)-2-oxazolidone [Example 14, m.p. 95.5 - 96.5 °C (recrystallized from ethyl acetate - hexane)] and 3-(7-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone [Example 15, m.p. 155 - 157 °C (recrystallized from ethyl acetate - hexane)] are obtained. Example 16 1.0ml of thionyl chloride is added to a suspension of 3.0g of sodium 6-(5-methoxymethyl-2-oxazolidone-3-yl)-2-naphthylsulfonate in 24ml of dimethylformamide under ice-cooling. The mixture is stirred at room temperature for one hour. After ice-cooling, the mixture is poured into ice-water and extracted with ethyl acetate. The extract is washed, dried and evaporated under reduced pressure to remove the solvent to give 2.9g of pale brown foam. The foam is dissolved in 50ml of tetrahydrofuran and 10ml of conc. aqueous ammonium hydroxide solution are added thereto. The mixture is stirred at room temperature for 2 hours. 200 ml of water are added to the mixture. The mixture is stirred for a minute and allowed to stand overnight at room temperature. Crystalline precipitates are collected and recrystallized from ethanol. 1.97g of 3-(6-aminosulfonyl-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless powder. m.p. 166 - 168 °C Example 17 18.9g of 3-(6-benzyloxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone is dissolved in 700ml of tetrahydrofuran and 10.0g of 10% of palladium - carbon are added thereto. The mixture is subjected to catalytic hydrogenation under atmospheric pressure at room temperature for 10 hours. The catalyst is filtered off, and the filtrate is evaporated under reduced pressure to remove the solvent. The residue is recrystallized from ethanol - tetrahydrofuran - isopropyl ether. 11.2g of 3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless needles. m.p. 192 - 193 °C Example 18 30.6g of 3-(6-benzyloxy-2-naphthyl)-5-tert.-butoxymethyl-2-oxazolidone are treated in the same manner as described in Example 17. 22.7g of 3-(6-hydroxy-2-naphthyl)-5-tert.-buthoxymethyl-2-oxazolidone are obtained as colorless crystals. m.p. 177 -178 °C (tetrahydrofuran - isopropyl ether - hexane) Example 19 5.06g of potassium carbonate and 2ml of ethyl iodide are added to a solution of 2.0g of 3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone in 25 ml of dimethyl formamide. The mixture is stirred for 4 hours at room temperature. The reaction mixture is diluted with ethyl acetate, washed with water and dried. The residue is recrystallized from ethyl acetate - isopropyl ether. 1.89g of 3-(6-ethoxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless plates. m.p. 129.5 - 130.5 °C Examples 20 to 46 The corresponding starting compounds are treated in the same manner as described in Example 19 to give a compounds shown in Table 6. Example 47 A mixture of 720mg of 3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone, 5ml of acrylonitrile, 5ml of tetrahydrofuran and 0.1ml of methanolic 40% benzyltrimethylammonium hydroxide solution is refluxed for 2 days. The reaction mixture is condensed under reduced pressure to dryness. The residue is extracted with ethyl acetate, and the extract is washed with water, dried and condensed under reduced pressure. The residue is purified by silica gel column chromatography [solvent: chloroform - methanol (20:1)] and recrystallized from ethyl acetate - hexane. 410mg of 3-(6-cyanoethoxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless scale. m.p. 110 - 112 °C Examples 48 to 50 The corresponding starting compounds are treated in the same manner as described in Example 47 to give the compounds shown in Table 7 Example 51 A mixture of 950mg of 3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone, 310mg of ethyl isocyanate, 15ml of methylene chloride, 10ml of tetrahydrofuran and one drop of triethylamine is stirred at room temperature for 4 hours. 1.5g of ethyl isocyanate are further added to the mixture, and the mixture is refluxed for 3 hours. The reaction mixture is condensed under reduced pressure. The residue is dissolved in ethyl acetate and washed with water treated with charcol and dried. The solvent is removed by evaporation under reduced pressure. The residue is recrystallized from ethyl acetate - isopropyl ether. 800mg of 3-(6-ethylaminocarbonyloxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless prisms m.p. 126.5 - 127.5 °C Example 52 A mixture of 2.0g of 3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone and 10ml of acetic anhydride is refluxed for one hour. The reaction mixture is evaporated to remove an excess acetic anhydride. The residue is recrystallized from ethyl acetate - isopropyl ether. 2.25g of 3-(6-acetyloxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless crystals. m.p. 110 - 112.5 °C Example 53 1.07g of m-chloroperbenzoic acid are gradually added at room temperature to a mixture of 1.88g of 5-methoxymethyl-3-[6-(methylthioethoxy)-2-naphthyl]-2-oxazolidone and 100ml of methylene chloride. The mixture is stirred at room temperature for one hour. The reaction mixture is washed with 10% aqueous sodium hydroxide solution and water, and then dried. The solvent is removed by evaporation under reduced pressure. The residue is purified by silica gel column chromatography [solvent: chloroform - methanol (30:1)] and recrystallized from ethyl acetate - tetrahydrofuran - isopropyl ether. 1.21g of 5-methoxymethyl-3-[6-(methylsulfinylethoxy)-2-naphthyl]-2-oxazolidone are obtained as colorless prisms. m.p. 133 - 141 °C Example 54 1.65g of m-chloroperbenzoic acid are gradually added at room temperature to a mixture of 1.20g of 5-methoxymethyl-3-[6-(methylthioethyloxy)-2-naphthyl]-2-oxazolidone and 40ml of methylene chloride. The mixture is stirred at room temperature for 3 hours. The reaction mixture is washed with 10% aqueous sodium hydroxide solution and water and then dried. The solvent is removed by evaporation under reduced pressure. The residue is purified by silica gel column chromatography [solvent: chloroform - ethyl acetate (1:1)] and then recrystallized from ethanol - tetrahydrofuran - isopropyl ether. 0.73g of 5-methoxymethyl-3-[6-(methylsulfonylethyloxy)-2-naphthyl]-2-oxazolidone are obtained as colorless needles. m.p. 128 - 129 °C Example 55 10ml of trifluoroacetic acid are added to 3.36g of 3-(2-naphthyl)-5-tert.-butoxymethyl-2-oxazolidone under ice-cooling. The mixture is stirred at room temperature for one hour. The reaction mixture is evaporated under reduced pressure to remove trifluoroacetic acid. The residue is recrystallized from ethanol - dimethylformamide - isopropyl ether. 2.16g of 5-hydroxymethyl-3-(2-naphthyl)-2-oxazolidone are obtained as colorless crystals m.p. 174 - 174.5 °C Examples 56 to 58 The corresponding starting compounds are treated in the same manner as described in Example 55 to give compounds shown in Table 8 Example 59 A mixture of 8.5g of methylsulfonyl chloride and 120 ml of methylene chloride is added dropwise to a suspension of 12.0g of 5-hydroxymethyl-3-(2-naphthyl)-2-oxazolidone. 240ml of methylene chloride and 10.0g of triethylamine under ice-cooling. The mixture is stirred at room temperature for 3 hours. A mixture of 1.0g of methylsulfonyl chloride and 50 ml of tetrahydrofuran is added dropwise to the mixture, and the mixture is stirred at room temperature for 2 hours. The reaction mixture is washed with water. The extract is dried, and then evaporated under reduced pressure to remove the solvent. The residue is recrystallized from isopropyl ether. 14.7g of 5-methylsulfonyloxymethyl-3-(2-naphthyl)-2-oxazolidone are obtained as colorless crystals. m.p. 169 - 172 °C Example 60 A mixture of 3.0g of 5-methylsulfonyloxymethyl-3-(2-naphthyl)-2-oxazolidone, 120ml of an aqueous 40% methylamine solution, 100ml of tetrahydrofuran and 50ml of dimethylformamide is stirred at room temperature in a sealed tube for 2 days. The reaction mixture is evaporated under reduced pressure to remove the excess methylamine and tetrahydrofuran. The mixture is extracted with ethyl acetate, and the extract is washed with water, dried evaporatedunder reduced pressure to remove the solvent. The residue is purified by silica gel column chromatography [solvent: chloroform - methanol (20:1)] and recrystallized from ethyl acetate - hexane. 1.12g of 5-methylaminomethyl-3-(2-naphthyl)-2-oxazolidone are obtained as colorless crystals. m.p. 76.5 - 78.0 °C Example 61 A mixture of 11.6g of 5-methylsulfonyloxymethyl-3-(2-naphthyl)-2-oxazolidone, 230ml of dimethylformamide, 4.84g of sodium azide and 23 ml of water is stirred at 80 °C for 9 hours. The reaction mixture is poured into water, extracted with ethyl acetate, and the extract is washed with water, dried and evaporated under reduced pressure to remove the solovent. The residue is recrystallized from ethyl acetate - hexane. 8.62g of 3-(2-naphthyl)-5-triazomethyl-2-oxazolidone are obtained as colorless crystals. m.p. 115.0 - 116.5 °C Example 62 8.35g of 3-(2-naphthyl)-5-triazomethyl-2-oxazolidone are dissolved in a mixture of 100 ml of tetrahydrofuran and 100 ml of acetic acid. 2.0g of 10% palladium - carbon are added to the solution. The mixture is subjected to catalytic hydrogenation at room temperature under atmospheric pressure. After the palladium - carbon is removed, the filtrate is evaporated under reduced pressure to remove the solvent. The residue is basified with an aqueous sodium bicarbonate solution. Crystalline precipitates are collected by filtration, and washed with water. The mixture is purified by silica gel column chromatography [solvent: chloroform - methanol (40:1 to 8:1)] and recrystallized from ethanol - isopropyl ether - hexane. 4.90g of 5-aminomethyl-3-(2-naphthyl)-2-oxazolidone are obtained as colorless crystals. m.p. 112 - 114 °C Example 63 A mixture of 1.8g of 5-aminomethyl-3-(2-naphthyl)-2-oxazolidone, 36ml of chloroform, 1.5ml of acetic anhydride and 1.5ml of pyridine is stirred at room temperature for one hour. The reaction mixture is washed with water, dried and evaporated under reduced pressure to remove the solvent. The residue is recrystallized from ethyl acetate - isopropyl ether. 1.56g of 5-acetylaminomethyl-3-(2-naphthyl)-2-oxazolidone are obtained as colorless crystals. m.p. 152 - 154 °C Example 64 (1) A mixture of 2.0g of 3-(6-benzyloxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone, 20ml of ethanol, 4ml of water and 1.08g of potassium hydroxide is stirred at 100 °C for one hour. The reaction mixture is evaporated under reduced pressure to remove the ethanol. The residue is extracted with ethyl acetate, and the extract is washed with water, dried and evaporated under reduced pressure to remove the solvent. The residue is recrystallized from ethyl acetate - hexane to give 1.64g of N-(3-methoxy-2-hydroxypropyl)-6-benzyloxy-2-naphthylamine as colorless needles. m.p. 103 - 104 °C (2) A mixture of 3.53g of ethyl chloroformate and 5 ml of methylene chloride is added dropwise to a mixture of 10.0g of the product obtained in the the paragraph (1), 70ml of methylene chloride, 70ml of water and 4.98g of sodium bicarbonate under ice-cooling. The mixture is stirred at room temperature for 1.5 hours. A mixture of 0.35g of ethyl chloroformate and 2ml of methylene chloride is added to the mixture, and the mixture is further stirred at room temperature for 4 hours. Organic layer is separated from the reaction mixture. The aqueous layer is extracted with methylene chloride and conbined with the organic layer. The conbined solution is dried and then evaporated under reduced pressure to remove the solvent. The residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (1:1)]. 12.66g of N-ethoxycarbonyl-N-(3-methoxy-2-hydroxypropyl)-6-benzyloxy-2-naphthylamine are obtained as colorless oil. Mass (m/z): 409 (M⁺), 318, 91 (base) (3) A mixture of 4.68g of pyridine and 10ml of tetrahydrofuran is added dropwise to a mixture of 12.12g of the product obtained in the paragraph (2). 120ml of tetrahydrofuran and 11.5g of (2S)-1-(2-naphthylsulfonyl)pyrrolidin-2-carbonyl chloride under ice-cooling. The mixture is stirred at room temperature for 3.5 hours. The reaction mixture is diluted with 500ml of ethyl acetate, washed with 5% hydrochloric acid and water, dried and evaporated to remove the solvent. The residue is purified by silica gel column chromatography [solvent: ethyl acetate - hexane (2:3)]. 9.48g of N-ethoxycarbonyl-N-((2R)-3-methoxy-2-[(2S)-1-(2-naphthylsulfonyl)pyrrolidin-2-carbonyloxy]propyl)-6-benzyloxy-2-naphthylamine (Product A) and 9.28g of N-ethoxycarbonyl-N-((2S)-3-methoxy-2-[(2S)-1-(2-naphthylsulfonyl)pyrrolidin-2-carbonyloxy]-propyl)-6-benzyloxy-2-naphthylamine (Product B) are obtained as colorless oils. Product A: [α] 20 / D -35.50° (c=0.569, chloroform) Product B: [α] 20 / D -56.42° (c=0.677, chloroform) (4) A mixture of 8.95g of Product A obtained in paragrapyh (3), 2.57g of sodium hydroxide, 100ml of ethanol and 20ml of water is stirred at 100 °C for one hour. The reaction mixture is evaporated under reduced pressure to remove the solvent, and water is added to the residue. The mixture is extracted with ethyl acetate. The extract is washed with water, dried and condenced. Hexane is added to the residue, and crystalline precipitates are collected by filtration. 3.76g of N-[(2R)-3-methoxy-2-hydroxypropyl]-6-benzyloxy-2-naphthylamine are obtained as colorless crystals. m.p. 105 - 106 °C [α] 20 / D -8.2° (c=0.533, chloroform) (5) A mixture of 3.65g of the product obtained in the paragraph (4), 70ml of dry methylene chloride, 3.51g of carbonyldiimidazol and 0.14g of diisopropylethylamine is stirred at room temperature for 2 hours. The reaction mixture is washed with 5% hydrochloric acid. The aqueous layer is extracted with ethyl acetate, and the extract is conbined with the organic layer. The mixture is dried and evaporated under reduced pressure to remove the solvent. The residue is recrystallized from ethyl acetate to give 3.60g of (5R)-3-(6-benzyloxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone as colorless scales. m.p. 150 - 150.5 °C [α] 20 / D -51.1° (c=0.305, chloroform) Example 65 (1) 9.2g of N-ethoxycarbonyl-N-((2S)-3-methoxy-2-[(2S)-1-(2-naphthylsulfonyl)-2-pyrrolidinylcarbonyloxy]propyl)-6-benzyloxy-2-naphthylamine are treated in the same manner as described in Example 64-(4). 3.76g of N-[(2S)-3-methoxy-2-hydroxypropyl]-6-benzyloxy-2-naphthylamine are obtained as colorless needles. m.p. 105 - 106 °C [α] 20 / D +7.90° (c=0.354, chloroform) (2) 3.62g of the product obtained in the paragraph (1) are treated in the same manner as described in Example 64-(5). 3.55g of (5S)-3-(6-benzyloxy-2-naphthy)-5-methoxymethyl-2-oxazolidone as colorless needles. m.p. 149.5 - 150.5 °C [α] 20 / D +49.9° (c=0.305, chloroform) Example 66 A mixture of 16.9g of (5R)-3-(6-benzyloxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone, 8.50g of 10% palladium-carbon and 400ml of tetrahydrofuran are hydrogenated at 45 to 50 °C for 2 hours under atmospheric pressure. Insoluble materials are filtered off. The filtrate is evaporated under reduced pressure to remove the solvent. The residue is recrystallized from tetrahydrofuran - isopropyl ether. 11.5g of (5R)-3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless prisms. m.p. 190 - 191 °C [α] 20 / D -74.0° (c=0.396, tetrahydrofuran) Example 67 15.0g of (5S)-3-(6-benzyloxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are treated in the same manner as described in Example 66. 10.3g of (5S)-3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless prisms. m.p. 190 - 191 °C [α] 20 / D +77.1° (c=0.358, tetrahydrofuran) Example 68 A mixture of 2.38g of (5R)-3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone, 1.83g of cyclopropylmethyl bromide, 3.55g of potassium carbonate and 30ml of dimethylformamide is stirred at 50 °C for 7 hours. The reaction mixture is poured into water, extracted with ethyl acetate. The extract is washed with water, dried and evaporated under reduced pressure to remove the solvent. The residue is purified by silica gel column chromatography [solvent: ethyl acetate - chloroform (1:10)] and recrystallized from ethyl acetate - hexane. 2.51g of (5R)-3-(6-cyclopropylmethoxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone are obtained as colorless scales. m.p. 120.5 - 121 °C [α] 20 / D -54.4° (c=1.08, chloroform) Example 69 3.69g of (55)-3-(6-hydroxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone and 2.84g of cycropropylmethyl bromide are treated in the same manner as described in Example 68. 4.07g of (5S)-3-(6-cyclopropylmethoxy-2-naphthyl)-5-methoxymethyl-2-oxazolidone as colorless scales. m.p. 119 - 119.5 °C [α] 20 / D +54.4° (c=1.05, chloroform)

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE A naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof. A compound claimed in Claim 1 in which an aryl group is phenyl group, and an oxygen-containing heteromonocyclic group is a tetrahydrofuryl group. A compound claimed in Claim 2 in which R¹ is a C₂₋₆ alkenyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from cyclopropyl group, hydroxy group and cyano group; R² is a C₁₋₆ alkoxy group. A compound claimed in Claim 3 in which R¹ is a C₁₋₆ alkoxy group which may have a substituent selected from cyclopropyl group and cyano group. A compound claimed in either one of Claim 1 to 4 in which R¹ is at 6-position of naphthalene ring and 5-substituted-2-oxazolidon-3-yl group is at 2-position of naphthalene ring. A pharmaceutical composition which comprises a pharmaceutically effective amount of the compound claimed in Claim 1 and a pharmaceutically acceptable carrier therefor. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a lower alkyl naphthylcarbamate compound of the formula: wherein R³ is a lower alkyl group and R¹ is the same as defined above, or a salt thereof with an oxirane compound of the formula: wherein R² is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthalene compound of the formula: wherein X¹ is a reactive residue, R¹ is the same as defined above, or a salt thereof with a 2-oxazolidone compound of the formula: wherein R² is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group, or a pharmaceutically acceptable salt thereof which comprises condensing a propanediol compound of the formula: wherein R¹ is the same as defined above, or a salt thereof with a carbonyl compound of the formula: CO(X²)₂ wherein X² is a reactive residue, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R⁴ is a C₁₋₆ alkyl group or a C₁₋₆ alkylsulfonyl group, or a pharmaceutically acceptable salt thereof which comprises condensing a naphthyloxazolidone derivative of the formula: wherein R¹ is the same as defined above, or a salt thereof with the compound of the formula: R⁴-X³ wherein X³ is a reactive residue, and R⁴ is the same as defined above, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof which comprises reducing a naphthyloxazolidone derivative of the formula: wherein R⁵ is an aryl-C₁₋₆ alkyl group, R² is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, R⁶ is a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a mono or di(C₁₋₆ alkyl)aminocarbonyl group, a C₂₋₆ alkanoyl group or a C₁₋₆ alkyl group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthyloxazolidone derivative of the formula: wherein R² is the same as defined above, or a salt thereof with a compound of the formula: R⁶-X⁴ wherein X⁴ is a reactive residue, R⁶ is the same as defined above, or a salt thereof, and,if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, R⁷ is cyano group or a (C₁₋₆ alkoxy)carbonyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthyloxazolidone derivative of the formula: wherein R² is the same as defined above, or a salt thereof with a compound of the formula: R⁷-CH=CH₂ wherein R⁷ is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, R⁸ is a C₁₋₆ alkyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthyloxazolidone derivative of the formula: wherein R² is the same as defined above, or a salt thereof with a C₁₋₆ alkyl isocyanate, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A lower alkyl naphthylcarbamate compound of the formula: wherein R¹ is nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group and R³ is a C₁₋₆ alkyl group, or a salt thereof. A propanediol compound of the formula: wherein R¹ is hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group, or a salt thereof. Claims for the following Contracting States : ES, GR A process for the preparation of a pharmaceutical preparation for the treatment of depressive conditions which comprises formulating a naphthyloxazolidon derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof to provide the pharmaceutical preparation, such as tablets, capsules, powders, granules or injections. A process as claimed in Claim 1 in which an aryl group is phenyl group, and an oxygen-containing heteromonocyclic group is a tetrahydrofuryl group. A process as claimed in Claim 2 in which R¹ is a C₂₋₆ alkenyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from cyclopropyl group, hydroxy group and cyano group; R² is a C₁₋₆ alkoxy group. A process as claimed in Claim 3 in which R¹ is a C₁₋₆ alkoxy group Which may have a substituent selected from cyclopropyl group and cyano group. A process as claimed in either one of Claim 1 to 4 in which R¹ is at 6-position of naphthalene ring and 5-substituted-2-oxazolidon-3-yl group is at 2-position of naphthalene ring. A process as claimed in any preceding claim which comprises a pharmaceutically effective amount of the naphthyloxazolidone derivative and a pharmaceutically acceptable carrier therefor. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a lower alkyl naphthylcarbamate compound of the formula: wherein R³ is a lower alkyl group and R¹ is the same as defined above, or a salt thereof with an oxirane compound of the formula: wherein R² is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthalene compound of the formula: wherein X¹ is a reactive residue, R¹ is the same as defined above, or a salt thereof with a 2-oxazolidone compound of the formula: wherein R² is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group, or a pharmaceutically acceptable salt thereof which comprises condensing a propanediol compound of the formula: wherein R¹ is the same as defined above, or a salt thereof with a carbonyl compound of the formula: CO(X²)₂ wherein X² is a reactive residue, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R¹ is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfonyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynyloxy group, a mono or di(C₁₋₆ alkyl)aminocarbonyloxy group, a C₂₋₆ alkanoyloxy group or a C₁₋₆ alkoxy group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group; R⁴ is a C₁₋₆ alkyl group or a C₁₋₆ alkylsulfonyl group, or a pharmaceutically acceptable salt thereof which comprises condensing a naphthyloxazolidone derivative of the formula: wherein R¹ is the same as defined above, or a salt thereof with the compound of the formula: R⁴-X³ wherein X³ is a reactive residue, and R⁴ is the same as defined above, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, or a pharmaceutically acceptable salt thereof which comprises reducing a naphthyloxazolidone derivative of the formula: wherein R⁵ is an aryl-C₁₋₆ alkyl group, R² is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, R⁶ is a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a mono or di(C₁₋₆ alkyl)aminocarbonyl group, a C₂₋₆ alkanoyl group or a C₁₋₆ alkyl group which may have a substituent selected from an aryl group, a C₃₋₆ cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a C₁₋₆ alkoxy group, cyano group, a di(C₁₋₆ alkyl)amino group, aminocarbonyl group, a (C₁₋₆ alkoxy)carbonyl group, a C₂₋₆ alkanoyloxy group, a C₁₋₆ alkylthio group, a C₁₋₆ alkylsulfinyl group and a C₁₋₆ alkylsulfonyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthyloxazolidone derivative of the formula: wherein R² is the same as defined above, or a salt thereof with a compound of the formula: R⁶-X⁴ wherein X⁴ is a reactive residue, R⁶ is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, R⁷ is cyano group or a (C₁₋₆ alkoxy)carbonyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthyloxazolidone derivative of the formula: wherein R² is the same as defined above, or a salt thereof with a compound of the formula: R⁷-CH=CH₂ wherein R⁷ is the same as defined above, or a salt thereof, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process for preparing a naphthyloxazolidone derivative of the formula: wherein R² is hydroxy group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a C₁₋₆ alkyl group and a C₂₋₆ alkanoyl group, R⁸ is a C₁₋₆ alkyl group, or a pharmaceutically acceptable salt thereof which comprises reacting a naphthyloxazolidone derivative of the formula: wherein R² is the same as defined above, or a salt thereof with a C₁₋₆ alkyl isocyanate, and, if required, converting the product into a pharmaceutically acceptable salt thereof. A process as claimed in any one of claims 7 to 14, wherein the resulting naphthyloxazolidone derivative is formulated to provide a pharmaceutical preparation, such as tablets, capsules, powders, granules or injections.

Inventors: IWATA HIROSHI, MATSUMOTO MAMORU, NAKAI HIDEO, NOMURA SUMIHIRO, YAMADA KOICHIRO, IWATA, HIROSHI, MATSUMOTO, MAMORU, NAKAI, HIDEO, NOMURA, SUMIHIRO, YAMADA, KOICHIRO
Applicants: TANABE SEIYAKU CO, TANABE SEIYAKU CO., LTD.
Application year: 1990
Main classification: C07D263
IPC codes: C07C309, C07C323, C07C271, C07C217, A61P25, A61K31, C07D307, C07C311, C07C317, C07C215, C07C219, C07D263, C07C255, C07C235, C07D413